Current perspectives on psychedelic treatments in Europe.

Psychedelic-assisted therapy in Europe is gaining momentum through recent initiatives in Switzerland, Germany, and the Czech Republic, though access remains limited. The authors argue for an integrative framework that considers neurobiological mechanisms, subjective experience, and contextual factors, emphasizing how effects involving neuroplasticity and critical periods may interact with psychotherapeutic processes. Context and psychological support are highlighted as crucial for shaping outcomes. Regulatory fragmentation and methodological complexities hinder progress, but publicly funded trials such as EPIsoDE and PsyPal offer promising examples of ethical and effective approaches. The future of psychedelic therapy lies in embracing its complexity.

Study at a glance

Abstract

In this viewpoint, we explore the evolving landscape of psychedelic-assisted therapy in Europe, focusing on clinical, regulatory, and therapeutic developments. While access remains limited, recent initiatives in Switzerland, Germany, and the Czech Republic illustrate growing momentum toward regulated use. We examine the debate surrounding psychedelics as pharmacological agents versus psychotherapeutic catalysts and argue for an integrative framework that considers neurobiological mechanisms, subjective experience, and contextual factors. We focus on how their effects, particularly those involving neuroplasticity and critical periods, may interact with psychotherapeutic processes. We highlight the importance of context and psychological support in shaping outcomes and discuss the challenges of implementing scalable care models. Regulatory fragmentation and methodological complexities continue to hinder progress, but publicly funded trials such as EPIsoDE and PsyPal offer promising examples of ethical and effective approaches. In our view, the future of psychedelic therapy lies not in simplifying its complexity, but in embracing it.